Bristol-Myers Squibb and Emory University announce partnership

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) and Emory University announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers Squibb's investigational compounds.

Under the newly established Master Clinical Trial Agreement, investigators from Emory University and affiliated institutions will conduct Phase II, Phase III and pediatric clinical trials in the metropolitan Atlanta area to support the ongoing development of investigational medicines from across Bristol-Myers Squibb's portfolio, particularly in oncology, metabolics, hepatitis C and immunoscience. This agreement builds on recent experiences between the two organizations in conducting clinical trials in organ transplantation and cancer.

In the first studies under the new agreement, researchers from the Winship Cancer Institute of Emory University will work with Bristol-Myers Squibb scientists on multiple clinical trial programs in oncology.

"This partnership is aligned with Bristol-Myers Squibb’s strategy, which embraces the opportunity to selectively integrate the expertise of other organizations with our own to best meet the treatment needs of patients," said Brian Daniels, senior vice president, Global Development & Medical Affairs, Bristol-Myers Squibb. "Our expectation is that the shared commitment of providing innovative solutions for patients, the world-class talent at both organizations and the clinical trial expertise at Emory, will result in important advancements in the understanding of Bristol-Myers Squibb compounds and their potential for treating patients with devastating diseases, such as cancer."

"Through this partnership, we are working to provide a framework to improve clinical trials efficiency and to enhance the development of academic and industry collaborations that solve health care problems," says David S. Stephens, MD, vice president for research in Emory's Woodruff Health Sciences Center and principal investigator of the Atlanta Clinical and Translational Science Institute (ACTSI). "Emory's successful partnership with Bristol-Myers Squibb in developing drugs for organ transplantation is an excellent example of the benefits of these kinds of collaborations."

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Emory University
Emory University is a leading educational and research institution that includes nine highly ranked colleges and professional schools and the state's most comprehensive health system. Emory's Woodruff Health Sciences Center is pioneering new ways to prevent and treat disease, driving technology-based economic development through translation of research into life-saving products, serving the local and global communities, and preparing the next generation to save and improve lives.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]